AR125033A1 - Formulación y métodos de gliburida de baja absorción - Google Patents
Formulación y métodos de gliburida de baja absorciónInfo
- Publication number
- AR125033A1 AR125033A1 ARP220100498A ARP220100498A AR125033A1 AR 125033 A1 AR125033 A1 AR 125033A1 AR P220100498 A ARP220100498 A AR P220100498A AR P220100498 A ARP220100498 A AR P220100498A AR 125033 A1 AR125033 A1 AR 125033A1
- Authority
- AR
- Argentina
- Prior art keywords
- glyburide
- salt
- racemate
- tautomer
- stereoisomer
- Prior art date
Links
- 229960004580 glibenclamide Drugs 0.000 title abstract 6
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 title abstract 6
- 238000009472 formulation Methods 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 238000010521 absorption reaction Methods 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 7
- 239000006172 buffering agent Substances 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 150000002148 esters Chemical class 0.000 abstract 4
- 239000012453 solvate Substances 0.000 abstract 4
- 150000005846 sugar alcohols Chemical class 0.000 abstract 3
- 208000028867 ischemia Diseases 0.000 abstract 2
- 239000008176 lyophilized powder Substances 0.000 abstract 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 abstract 1
- 206010052346 Brain contusion Diseases 0.000 abstract 1
- 208000032843 Hemorrhage Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010040047 Sepsis Diseases 0.000 abstract 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 abstract 1
- 230000009516 brain contusion Effects 0.000 abstract 1
- 230000003139 buffering effect Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000012535 impurity Substances 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 230000035939 shock Effects 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
- 238000001179 sorption measurement Methods 0.000 abstract 1
- 208000020431 spinal cord injury Diseases 0.000 abstract 1
- 230000009529 traumatic brain injury Effects 0.000 abstract 1
- 239000002699 waste material Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/52—Y being a hetero atom
- C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
- C07C311/57—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
- C07C311/58—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/52—Y being a hetero atom
- C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
- C07C311/57—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
- C07C311/59—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of rings other than six-membered aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Métodos y formulaciones para minimizar o evitar la sorción de gliburida en las superficies de los tubos de suministro, filtros, bolsas y otros recipientes y materiales, almacenando y suministrando así un producto más estable, suministrando una dosis predecible y precisa de la gliburida, al tiempo que minimiza las impurezas, evita el desperdicio de medicamentos, reduce los costos y reduce significativamente la cantidad de solución de dosificación (generalmente solución salina o solución de Ringer) que se debe infundir al paciente. Reivindicación 1: Una formulación que comprende: a. gliburida o una sal farmacéuticamente aceptable de esta; b. un agente amortiguador; c. una base; y d. un alcohol de azúcar, donde la formulación tiene un pH fuera de la capacidad amortiguadora del agente amortiguador. Reivindicación 77: Un compuesto que tiene la estructura de fórmula (1) o una de sus sales, ésteres, hidratos, solvatos, racematos, tautómeros, estereoisómeros o formas ópticamente activas. Reivindicación 81: Un método para tratar a un paciente que sufre de accidente cerebrovascular, hemorragia, inflamación de células neuronales, lesión cerebral traumática, lesión de la médula espinal, isquemia de órganos, síndrome coronario agudo, infarto de miocardio, sepsis, contusión cerebral, shock, isquemia o arritmia ventricular que comprende administrar la formulación o kit de cualquiera de las reivindicaciones anteriores. Reivindicación 87: Un compuesto que tiene la siguiente estructura de fórmula (2) o una de sus sales, ésteres, hidratos, solvatos, racematos, tautómeros, estereoisómeros o formas ópticamente activas. Reivindicación 91: Un compuesto que tiene la siguiente estructura de fórmula (3) o una de sus sales, ésteres, hidratos, solvatos, racematos, tautómeros, estereoisómeros o formas ópticamente activas. Reivindicación 93: Un compuesto que tiene la siguiente estructura de fórmula (4) o una de sus sales, ésteres, hidratos, solvatos, racematos, tautómeros, estereoisómeros o formas ópticamente activas. Reivindicación 95: Un polvo liofilizado que comprende: 0,2 a 10,8% en peso de gliburida o una sal farmacéuticamente aceptable de esta; 4,4 a 8,8% en peso de un agente amortiguador; 80,1 a 94% en peso de un alcohol de azúcar; y una base. Reivindicación 106: Un polvo liofilizado que comprende: a) gliburida o una sal farmacéuticamente aceptable de esta; b) un agente amortiguador; c) un alcohol de azúcar; y d) una base, en una relación molar de 0,00038 a 0,02186 (a) : 0,032 a 0,063 (b) : 0,440 a 0,516 (c) : 0,021 a 0,042 (d).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163156533P | 2021-03-04 | 2021-03-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR125033A1 true AR125033A1 (es) | 2023-05-31 |
Family
ID=80930067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220100498A AR125033A1 (es) | 2021-03-04 | 2022-03-04 | Formulación y métodos de gliburida de baja absorción |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220280537A1 (es) |
| EP (1) | EP4301337A2 (es) |
| JP (1) | JP2024512310A (es) |
| KR (1) | KR20230165778A (es) |
| CN (1) | CN117320727A (es) |
| AR (1) | AR125033A1 (es) |
| CA (1) | CA3210407A1 (es) |
| MX (1) | MX2023010313A (es) |
| TW (1) | TW202302117A (es) |
| UY (1) | UY39658A (es) |
| WO (1) | WO2022187567A2 (es) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1269578B (it) * | 1994-04-22 | 1997-04-08 | Chiesi Farma Spa | Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base. |
| EP1957028B1 (en) | 2005-10-30 | 2017-06-07 | Medimop Medical Projects Ltd. | Needleless additive control valve |
| GB2578705B (en) | 2013-08-07 | 2020-11-11 | West Pharmaceutical Services Il Ltd | Liquid transfer devices for use with infusion liquid containers |
| CN108210501B (zh) * | 2016-12-14 | 2019-03-08 | 中国人民解放军军事医学科学院毒物药物研究所 | 一种磺酰脲类药物的注射用药物组合物及其制备方法 |
-
2022
- 2022-03-04 TW TW111107963A patent/TW202302117A/zh unknown
- 2022-03-04 US US17/686,538 patent/US20220280537A1/en active Pending
- 2022-03-04 JP JP2023553299A patent/JP2024512310A/ja active Pending
- 2022-03-04 EP EP22712158.9A patent/EP4301337A2/en active Pending
- 2022-03-04 CN CN202280032626.3A patent/CN117320727A/zh active Pending
- 2022-03-04 CA CA3210407A patent/CA3210407A1/en active Pending
- 2022-03-04 UY UY0001039658A patent/UY39658A/es unknown
- 2022-03-04 MX MX2023010313A patent/MX2023010313A/es unknown
- 2022-03-04 AR ARP220100498A patent/AR125033A1/es unknown
- 2022-03-04 WO PCT/US2022/018821 patent/WO2022187567A2/en active Application Filing
- 2022-03-04 KR KR1020237033801A patent/KR20230165778A/ko unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230165778A (ko) | 2023-12-05 |
| WO2022187567A2 (en) | 2022-09-09 |
| EP4301337A2 (en) | 2024-01-10 |
| WO2022187567A3 (en) | 2022-10-20 |
| CN117320727A (zh) | 2023-12-29 |
| MX2023010313A (es) | 2023-11-24 |
| JP2024512310A (ja) | 2024-03-19 |
| US20220280537A1 (en) | 2022-09-08 |
| UY39658A (es) | 2022-09-30 |
| CA3210407A1 (en) | 2022-09-09 |
| TW202302117A (zh) | 2023-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230159628A1 (en) | Anti-CGRP Antibody Formulation | |
| KR101544246B1 (ko) | 프로스타시클린 유사체의 고체 제제 | |
| US9168238B2 (en) | Levothyroxine formulations | |
| ES2158911T5 (es) | Formulaciones en aerosol sin clorofluorocarbonos. | |
| US20090054331A1 (en) | High temperature stable peptide formulation | |
| ES2213744T3 (es) | Composiciones farmaceuticas a base de inhibidores de la interleucina-1. | |
| ES2298672T3 (es) | Composiciones que contienen piperacilina y tazobactam utiles para inyeccion. | |
| CZ287178B6 (en) | Stable lyophilized pharmaceutical preparation | |
| JP7268079B2 (ja) | ナノ粒子凍結乾燥形態のための組成物および方法 | |
| JP7443443B2 (ja) | 関節を治療するための組成物及びキット | |
| ES2554167T3 (es) | Métodos y composiciones útiles en el tratamiento de mucositis | |
| ES2244625T3 (es) | Uso de derivados de biguanida para la fabricacion de un medicamento con efecto cicatrizante. | |
| AU709785B2 (en) | Stable solutions of 2-chloro-2'-deoxyadenosine formulations | |
| BRPI0612447A2 (pt) | composição antibiótica de dose fixa, processo para a preparação de um produto de combinação antibiótica de dose fixa, processo para a preparação de uma injeção lìquida e usos de pó seco para injeção e injeção lìquida | |
| AR042977A1 (es) | Formulaciones farmaceuticas liquidas de palonosetron | |
| JP2018188399A (ja) | テリパラチドのプレフィルドシリンジ製剤 | |
| AR125033A1 (es) | Formulación y métodos de gliburida de baja absorción | |
| JP7314986B2 (ja) | 眼科用製品及び粘度低下抑制方法 | |
| JP2020536089A5 (es) | ||
| WO1995022560A1 (en) | Pharmaceutical formulations of cntf | |
| US20190314449A1 (en) | Cyclic dipeptides and wound healing | |
| MX9304197A (es) | Nuevo uso de dimero de lisozina y composiciones que lo contienen. | |
| TW202228714A (zh) | 一種水通道蛋白抑制劑的藥物組合物及其製備方法 | |
| JP2009538822A5 (es) | ||
| CN112472667B (zh) | 一种维他昔布长效注射液及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |